Long for a Longtime or until they make me an offer I cant' Refuse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why don't you give us a link or two to one of these enlighten scientists....Thanks
Great post Xena!
Could the delay in the release of data have something to do with Anavex working with the FDA to create a Phase 2/3 fast track trail design?
Thanks for the update...pretty much what I expected...glad to hear the group had a positive opinion.
I always felt MS used his AVXL short $$$$$ to buy KBIO... the timing was right.
SA masters of misinformation.... no accident IMO
What company are you talking about? and show me some links.
Anyone who has cared for a person with AD, understands a Placebo effect or any other kind of effect would probably last less than a day maybe a minute.
Also Dr. MAC expressed this point.
The fact that they are recruiting for the next phase tells me all I need to know...Anavex's whole approach to these trails was to prove that the drug works so they would not fail in phase 3.... and keep in mind the end points on these trails is evolving...what was anecdotal may now be significant if proven.
BINGO!
Let the games begin!!!
A whole lot of assumptions and the same old same old from pre Dr. M era.
No options expiring...
Professor Paul Maruff, Chief Scientific Officer of Cogstate commented: “The Cogstate tests measure people’s ability to store and use information. The results of the Phase 2a study demonstrate that ANAVEX 2-73 improves psychomotor function, attention and working memory. For attention and working memory these improvements were statistically significant with a p-value of p<0.05 and p<0.001, respectively and their magnitude clinically important. To my knowledge, we have not yet seen a drug that has improved quantitatively working memory to such an extent as seen with ANAVEX 2-73”.
03-30-2016 CTFR Final Rejection
03-30-2016 FWCLM Index of Claims PROSECUTION
03-30-2016 SRFW Search information including classification, databases and other search related notes
More info on http://portal.uspto.gov/pair/PublicPair ...13/940,352
The Good Doctor at the Epilepsy Pipeline conference.
http://www.epilepsy.com/accelerating-new-therapies/2016-epilepsy-pipeline-conference/session-ix-clinical-drugs#14
The difference between mice and men....
Sounds like they rejected the 2-73 plus patent application..there was no documentation explaining why... Based on the last PR 2-73 seems to work the same as 2-73 plus.. this should be a none issue...IMO
http://portal.uspto.gov/pair/PublicPair 13/940,352 under transaction history
03-25-2016 Final Rejection
From Public Pair 13/940,352 2-73 plus
I don't think so..
FBR Capital initiates coverage on Anavex Life Sciences (NASDAQ: AVXL) with a Outperform rating and a $10.00 price target.
Miss A.
Thank you for your input....Please ignore the noise that persists on this board.
I love it how all these Guys are trying to set us all up for failure..
And 123 give it a break!
The Data will will released when it available!!!!
Probably the last buying opportunity...Keep it going softy...
He said "this quarter when we get the data"
Around 24 minutes in.
https://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm?0.0513142788836
I show 5250 shares @ 12:05...must have been a hicup
2-73 pre-clinical looked pretty damn good for epilepsy.
Just one indication...Rett's gets us to off label market..quickly!
In the phase III study, treatment with the GW Pharma drug, Epidiolex, resulted in a 39% reduction in monthly convulsive seizures compared to a 13% reduction for placebo. The difference was statistically significant.
Retts fast track gets us to market quickly....
Potential to advance ANAVEX 2-73 in a Phase 2 exploratory
clinical trial for rare disease indication, Rett syndrome
PR heading told the story.
The most significant take away...IMO
Similar positive MMSE score effect and no notable difference between
ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil observed
"We don't need no stinkin' patent"
The FDA is the target of the good doctors affections..
The company will also present detailed dose-response analysis of data from the ongoing Phase 2a Alzheimer’s trial of ANAVEX 2-73 PART A at the 14th International Symposium on Advances in Alzheimer Therapy (AAT),
No 12 week..... IMO
As always ... Great post JB
Good to see some of the old timers posting.... If good, the 12 week and maybe 26 week data will be very significant... it will prove that the drug works... IMO
Anavex 3-71
AF710B is a promising novel therapeutic agent for the treatment of AD.
Page 175 http://www.siumed.edu/cpd/alzheimer/pdf/2016abstracts.pdf
Yeah I missed that sell...Looking for $4.93... ;)
Also keep in mind they have 26 week data (original end point) on at least 14 patients. Could very well announce begining of Ph2/3.
It is going to be interesting to see how the crooks deal with this one...will the Twitter Babe show up again in Athens??? Is Papa Troll writing more lies???
I will take credit for this....I posted on the anavex FB page...LOL
http://www.anavex.com/?events=14th-international-athens-springfield-symposium-on-advances-in-alzheimer-therapy
I see our painter had a bigger brush today..